These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34339089)

  • 41. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
    Castrejon I; Toledano E; Rosario MP; Loza E; Pérez-Ruiz F; Carmona L
    Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
    Singh JA; Yang S; Saag KG
    J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inequities in people with gout: a focus on Māori (Indigenous People) of Aotearoa New Zealand.
    Te Karu L; Dalbeth N; Stamp LK
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211028007. PubMed ID: 34262623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L; Gow P; Sharples K; Raill B
    Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
    Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol.
    Dalbeth N; Nicolaou S; Baumgartner S; Hu J; Fung M; Choi HK
    Ann Rheum Dis; 2018 Mar; 77(3):364-370. PubMed ID: 29146741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system.
    Mikuls TR; Curtis JR; Allison JJ; Hicks RW; Saag KG
    J Rheumatol; 2006 Mar; 33(3):562-6. PubMed ID: 16482645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.
    Kim SC; Schmidt BM; Franklin JM; Liu J; Solomon DH; Schneeweiss S
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2008-14. PubMed ID: 23861232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
    Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Up-titration of allopurinol in patients with gout.
    Jennings CG; Mackenzie IS; Flynn R; Ford I; Nuki G; De Caterina R; Riches PL; Ralston SH; MacDonald TM;
    Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patient-reported gout attack frequency and allopurinol use in general practice in the Netherlands: a prospective observational cohort study protocol.
    van Leeuwen KDB; Bohnen AM; Jacobs ML; van Der Lei J; Janssens HJEM; Koffeman AR; Bindels PJE; Bierma-Zeinstra SMA
    BMJ Open; 2018 Nov; 8(11):e024335. PubMed ID: 30478125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gout characteristics associate with depression, but not anxiety, in primary care: Baseline findings from a prospective cohort study.
    Prior JA; Mallen CD; Chandratre P; Muller S; Richardson J; Roddy E
    Joint Bone Spine; 2016 Oct; 83(5):553-8. PubMed ID: 27068619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
    Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP; Gilliland WR
    Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial.
    Arroll B; Bennett M; Dalbeth N; Hettiarachchi D; Ben C; Shelling G
    J Prim Health Care; 2009 Dec; 1(4):315-8. PubMed ID: 20690341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
    Mikuls TR; Cheetham TC; Levy GD; Rashid N; Kerimian A; Low KJ; Coburn BW; Redden DT; Saag KG; Foster PJ; Chen L; Curtis JR
    Am J Med; 2019 Mar; 132(3):354-361. PubMed ID: 30503879
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.